Expression of human CD59 in transgenic pig organs enhances organ survival in an ex vivo xenogeneic perfusion model

Transplantation

Volumn 61, Issue 10, 1996, Pages 1513-1521

  Kroshus, Timothy J ^a   Bolman III, R Morton ^a,d   Dalmasso, Agustin P ^b   Rollins, Scott A ^c   Guilmette, Edward R ^c   Williams, Barry L ^c   Squinto, Stephen P ^c   Fodor, William L ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c ALEXION PHARMACEUTICALS   (United States)

^d Dept Cardiovasc and Thorac Surg ^*

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOPATHOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; XENOGRAFT; XENOTRANSPLANTATION;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIGENS, CD59; BASE SEQUENCE; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT C9; DISEASE MODELS, ANIMAL; DNA PRIMERS; GRAFT REJECTION; HEART; HEMOLYSIS; HUMANS; KIDNEY; LEUKOCYTES, MONONUCLEAR; MOLECULAR SEQUENCE DATA; PERFUSION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0030008604     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199605270-00018     Document Type: Article

References (30)

1. Sommerville CA, D'Apice AJF. Future directions in transplantation: xenotransplantation. Kidney Int 1993; 44 (suppl.) 42: S112.
2. Dalmasso AP, Vercellotti GM, Fischel RJ, Bolman RM, Bach FH, Platt JL. Mechanism of complement activation in the hyperacute rejection of porcine organs transplanted into primate recipients. Am J Pathol 1992; 140: 1157.
3. Auchincloss H Jr. Xenografting: a review. Transplant Rev 1990; 4: 14.
4. Platt JL, Vercellotti GM, Dalmasso AP, et al. Transplantation of discordant xenografts: a review of progress. Immunol Today 1990; 11: 450.
5. Platt JL, Lindman BJ, Chen H, Spitalnik SL, Bach FH. Endothelial cell antigens recognized by xenoreactive natural antibodies. Transplantation 1990; 50: 817.
6. Sandrin MS, Vaughan HA, Dabkowski PL, McKenzie IFC. anti-pig IgM antibodies in human serum react predominately with Gal(α1-3)Gal epitopes. Proc Natl Acad Sci USA 1993; 90: 11391.
7. Larsen RD, Rivera-Marrero CA, Ernst LK, Cumming RD, Lowe JB. Frameshift and nonsense mutations in a human genomic sequence homologous to a murine UDP-Gal: beta-D-Gal(1,4)-D-GlcNAc alpha(1,3)-galactosyltransferase. J Biol Chem 1990; 265: 7055.
8. Dalmasso AP. The complement system in xenotransplantation. Immunophamacology 1992; 24: 149.
9. Leventhal JR, Dalmasso AP, Cromwell JW, et al. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 1993; 55: 857.
10. Pruitt SK, Kirk AD, Bollinger RR, et al. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 1994; 57: 363.
11. Kroshus TJ, Rollins SA, Dalmasso AP, et al. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation. Transplantation (in press).
12. Leventhal JR, John R, Fryer JP, et.al. Removal of baboon and human antiporcine IgG and IgM natural antibodies by immunoadsorption. Transplantation 1995; 59: 294.
13. Brewer RJ, Del Rio MJ, Roslin MS, et al. Depletion of preformed antibody in primates for discordant xenotransplantation by continuous donor organ plasma perfusion. Transplant Proc 1993; 25: 385.
14. Kroshus TJ, Dalmasso AP, Leventhal JR, John R, Matas AJ, Bolman RM. Antibody removal by column immunoabsorption prevents tissue injury in an ex vivo model of pig-to-human xenograft hyperacute rejection. J Surg Res 1995 (in press).
15. Cooper DKC, Good AH, Ye Y, et al. Specific intravenous carbohyrate therapy: a new approach to the inhibition of antibody-mediated rejection following ABO-incompatible allografting and discordant xenografting. Transplant Proc 1993; 25: 377.
16. Fodor WL, Williams BL, Rollins SA. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc Natl Acad Sci USA 1994; 91: 11153.
17. Rosengard AM, Cary NRB, Lagford GA, Tucker AW, Wallwork J, White DJG. Tissue expression of human complement inhibitor, decay accelerating factor, in trasngenic pigs. Transplantation 1995; 59: 1325.
18. McCurry KR, Kooyman DL, Alvarado CG, et al. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nature Med 1995; 1: 423.
19. Dalmasso AP, Vercellotti GM, Platt JL, Bach FH. Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor. Transplantation 1991; 52: 533.
20. Kennedy SP, Rollins SA, Burton WV, et al. Protection of porcine aortic endothelial cells from complement-mediated cell lysis and activation by recombinant human CD59. Transplantation 1994; 57: 1494.
21. Rolling SA, Zhao J, Ninomiya H, Sims PJ. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-9 or C9 within C5b-9. J Immunol 1991; 146: 2345.
22. Lachmann PJ. The control of homologous lysis. Immunol Today 1991; 12: 312.
23. Platt JL, Turman MA, Noreen HJ, Fischel RJ, Bolman RM, Bach FH. An ELISA assay for xenoreactive natural antibodies. Transplantation 1990; 49: 1000.
24. Kent JF, Fife EH Jr. Precise standardization of reagents for complement fixation. Am J Trop Med 1963; 12: 103.
25. Laine RO, Esser AF. Identification of the discontinuous epitope in human complement protein C9 recognized by anti-melitin antibodies. J Immunol 1989; 143: 553.
26. Falk RJ, Dalmasso AP, Kim V, et al. Neoantigen of the polymerized ninth component of complement: characterization of a monoclonal antibody and immunohistochemical localization in renal disease. J Clin Invest 1983; 72: 560.
27. Brauer RB, Baldwin WM III, Daha MR, Pruitt SK, Sanfilippo F. Use of CG-deficient rats to evaluate the mechanism of hyperacute rejection of discordant cardiac xenografts. J Immunol 1993; 151: 7240.
28. Brooimans RA, Wieringen PAM, Van Es LA, Daha MR. Relative roles of decay-accelerating factor, membrane cofactor, and CD59 in the protection of human endothelial cells against complement-mediated lysis. Euro J Immunol 1992; 22: 3135.
29. Platt JL, Vercellotti GM, Lindman B, Oegema TR Jr, Bach FH, Dalmasso AP. Release of heparan sulfate from endothelial cells: implications for pathogenesis of hyperacute rejection. J Exp Med 1990; 171: 1363.
30. Hamilton KK, Zhao J, Rollins SA, Stewart BH, Sims PJ. Regulatory control of the terminal complement proteins at the surface of human endothelial cells: neutralization of a C5b-9 inhibitor by antibody to CD59. Blood 1990; 76: 2572.